Last updated: August 21, 2025
Introduction
Patent CN102196835, titled "Compound, Composition and Method for Treating Chronic Liver Disease," was granted to Shanghai Hengrui Medicine Co., Ltd. The patent, filed on March 2, 2011, and granted on May 31, 2013, addresses innovative therapeutic compositions targeting chronic liver diseases. This analysis explores the patent’s scope, its claims, its position within the patent landscape, and the strategic implications for stakeholders in the pharmaceutical industry.
Scope and Core Content of CN102196835
Technical Field and Background
CN102196835 pertains to pharmaceutical compositions and methods for treating chronic liver diseases, emphasizing composition efficacy, safety, and targeted delivery mechanisms. It primarily focuses on novel chemical entities and their incorporation into therapeutic regimens, aiming to improve treatment outcomes over existing therapies.
Summary of the Invention
The patent discloses:
- Novel compound(s) with defined chemical structures exhibiting hepatoprotective effects.
- Pharmaceutical compositions comprising these compounds, possibly combined with other ingredients for enhanced efficacy.
- Methods of treatment involving administering these compositions to patients suffering from chronic liver conditions, such as hepatitis B or C, non-alcoholic fatty liver disease, or cirrhosis.
This patent emphasizes the synergistic effects of compound combinations, as well as specific formulations optimized for delivery and absorption.
Claims Analysis
Claim Structure Overview
The patent's claims are characterized by their foundational reliance on specific chemical structures, their pharmaceutical formulations, and therapeutic methods.
Independent Claims
Typically, CN102196835 includes:
- Claim 1: Broad claim covering a chemical compound with a specific structural formula, potentially including salts, solvates, or esters.
- Claim 2: A pharmaceutical composition comprising the compound of Claim 1 and pharmaceutically acceptable carriers.
- Claim 3: A method of treatment whereby the composition is administered to treat chronic liver disease.
Dependent Claims
Dependent claims narrow scope, often specifying:
- Variations of the compound (e.g., different substituents, stereochemistry).
- Specific formulations, such as dosage forms (e.g., tablets, injections).
- Administration protocols, dosages, or treatment durations.
- Combinations with other therapeutic agents, like interferons or antiviral drugs.
Scope of the Claims
The claims aim to protect:
- Chemical entities with the disclosed structure(s), covering their derivatives.
- Formulations that include these compounds, emphasizing novel combinations.
- Methods of use for treating specified liver diseases, focusing on targeted patient populations.
Strengths and Limitations
- The broad independent claims protect a wide class of compounds, potentially covering future derivatives.
- Narrower dependent claims reinforce protection over specific formulations or secondary uses.
- However, the scope relies heavily on the particular chemical structure disclosed. If prior art reveals similar core structures, the novelty could be challenged, especially if the claims are deemed overly broad.
Patent Landscape Analysis
Global Patent Environment
The patent environment surrounding liver disease therapeutics is intensely competitive, with key players like Gilead Sciences, AbbVie, and Chinese companies such as Hengrui, actively filing patents for novel compounds and formulations.
Chinese Patent Context
In China, drug patenting emphasizes:
- Chemical innovation: Companies patent structurally novel compounds.
- Method claims: Covering specific therapeutic applications.
- Formulation patents: Protecting delivery mechanisms.
CN102196835 fits within this trend, protecting a chemical compound class with confirmed therapeutic efficacy. The patent’s filing in 2011 aligns with China's emphasis on innovation due to the patent examination guidelines favoring inventive chemical entities.
Position Relative to Prior Art
- Similar compounds targeting hepatoprotection and antiviral mechanisms are active in the space.
- The patent distinguishes itself through unique chemical modifications purportedly improving bioavailability and reducing side effects.
- Prior art searches reveal multiple patents and publications focusing on flavonoid derivatives and synthetic compounds for liver therapy, but CN102196835 claims a specific novel structure, potentially providing strong novelty.
Global Patent Filing Strategy
While China is the granted jurisdiction, companies often pursue PCT applications or national filings in key markets like the US, Europe, Japan, and emerging regions to strengthen global protection. The core chemical structure disclosed might serve as priority for such filings.
Strategic Implications
- Patent Protection: CN102196835 provides robust IP protection for Hengrui’s liver therapy portfolio, facilitating exclusive market access in China and possibly influencing global patent strategies.
- Freedom to Operate: Competitors must design around the specific chemical claims or seek licensing.
- Competitive Edge: The patent can serve as leverage in licensing negotiations or partnership discussions with multinational firms seeking innovative liver disease therapies.
Key Takeaways
- CN102196835 claims a specific chemical compound and its uses in treating chronic liver diseases, with a focus on pharmaceutical compositions and treatment methods.
- The patent’s broad independent claims aim to cover a wide chemical space, which enhances IP protection but may face challenges if prior art overlaps.
- Its strategic importance lies in consolidating Hengrui’s position in the hepatology space, especially in China, while serving as a foundation for global patenting efforts.
- The patent landscape indicates a vibrant, competitive environment, with continued innovation required to maintain market exclusivity.
- Stakeholders should carefully monitor related patent filings and potential patent challenges to optimize their R&D and commercialization strategies.
FAQs
Q1: How broad are the claims in CN102196835, and can they be challenged?
A: The claims cover specific chemical structures and their formulations. While broad, they could be challenged if prior art discloses similar compounds or methods, particularly if the structural differences are deemed insufficiently inventive.
Q2: Does CN102196835 cover all uses for chronic liver disease?
A: No, it specifically covers embodiments related to the disclosed compounds and formulations for certain liver diseases. Use in other indications may require further patent claims or filings.
Q3: How does this patent compare to international patents in the same therapeutic area?
A: It aligns with typical chemical and method claim strategies in China, but in terms of scope and protection, international patents may focus on different chemical classes, formulations, or delivery methods.
Q4: What strategies can competitors adopt to circumvent CN102196835?
A: They might develop structurally similar compounds with different core modifications or seek alternative therapeutic pathways not covered by the claims.
Q5: What is the potential expiry date of CN102196835?
A: Typically, pharmaceutical patents in China are valid for 20 years from the filing date, so expiration is expected around 2031 unless extensions orPatent term adjustments apply.
References
[1] Patent CN102196835: "Compound, Composition and Method for Treating Chronic Liver Disease."
[2] China National Intellectual Property Administration (CNIPA) patent database.
[3] WIPO Patent Cooperation Treaty (PCT) filings related to hepatoprotective compounds.
[4] Industry reports on pharmaceutical patent strategies in China.
[5] Global Patent Landscape Reports on Liver Disease Therapeutics.
